Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer's ...

Eisai will request a reconsideration of this decision under Section 60* of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia.

Here are the stories you need to start your day including; how to get the best deal from your mobile phone provider and the rise and rise of the 2 Johnnies ...

US President Joe Biden announced a $425 million arms package for Kyiv Wednesday in a call with President Volodymyr Zelensky, ahead of a farewell visit to Berlin to discuss Ukraine, the White House ...